CN1205190C - 制备3(2h)-哒嗪酮-4-取代氨基-5-氯-衍生物的方法 - Google Patents
制备3(2h)-哒嗪酮-4-取代氨基-5-氯-衍生物的方法 Download PDFInfo
- Publication number
- CN1205190C CN1205190C CNB988141701A CN98814170A CN1205190C CN 1205190 C CN1205190 C CN 1205190C CN B988141701 A CNB988141701 A CN B988141701A CN 98814170 A CN98814170 A CN 98814170A CN 1205190 C CN1205190 C CN 1205190C
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- reaction
- amino
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 16
- 239000002253 acid Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 75
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- -1 mesyloxy, phenylsulfonyloxy Chemical group 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003999 initiator Substances 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- GBAOOJAWDCNOGO-UHFFFAOYSA-N 3,4,5-trichloropyridazine Chemical compound ClC1=CN=NC(Cl)=C1Cl GBAOOJAWDCNOGO-UHFFFAOYSA-N 0.000 abstract 1
- UUMQGMCYAJYYQR-UHFFFAOYSA-N 4-chloro-5-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propylamino]-1h-pyridazin-6-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCNC1=C(Cl)C=NNC1=O UUMQGMCYAJYYQR-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YPJDGPDZLPYDNJ-UHFFFAOYSA-N 5-(3-bromopropylamino)-4-chloro-1h-pyridazin-6-one Chemical compound ClC=1C=NNC(=O)C=1NCCCBr YPJDGPDZLPYDNJ-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 229960001701 chloroform Drugs 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FPCLISZEWJIVEW-UHFFFAOYSA-N 2-chloropyridazin-3-one Chemical class ClN1N=CC=CC1=O FPCLISZEWJIVEW-UHFFFAOYSA-N 0.000 description 3
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000005826 halohydrocarbons Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HNJWKRMESUMDQE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(OC)C(OC)=C1 HNJWKRMESUMDQE-UHFFFAOYSA-N 0.000 description 2
- IBWYHNOFSKJKKY-UHFFFAOYSA-N 3-chloropyridazine Chemical class ClC1=CC=CN=N1 IBWYHNOFSKJKKY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229910014033 C-OH Inorganic materials 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910014570 C—OH Inorganic materials 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- MMDLBXYSCAXZNC-UHFFFAOYSA-N [C].C1=CC=NN=C1 Chemical group [C].C1=CC=NN=C1 MMDLBXYSCAXZNC-UHFFFAOYSA-N 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 239000003849 aromatic solvent Substances 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FKVPPMFFHJGQIX-UHFFFAOYSA-N 3-[(3,5-dichloropyridazin-4-yl)amino]propan-1-ol Chemical compound OCCCNC1=C(Cl)C=NN=C1Cl FKVPPMFFHJGQIX-UHFFFAOYSA-N 0.000 description 1
- JGUMPVKBBFBMAV-UHFFFAOYSA-N 3-[(5,6-dichloropyridazin-4-yl)amino]propan-1-ol Chemical compound OCCCNC1=CN=NC(Cl)=C1Cl JGUMPVKBBFBMAV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 125000006416 CBr Chemical group BrC* 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/12—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明涉及制备式(I)5-氯-4-{3-[N-[2-(3,4-二甲氧基苯基)-乙基]-N-甲基-氨基]-丙基氨基}-3(2H)-哒嗪酮及其可药用酸加成盐的新方法。本发明的一个重要特征是使用3,4,5,-三氯哒嗪作为合成的起始物。
Description
本发明涉及制备式(I)5-氯-4-{3-[N-[2-[3,4-二甲氧基苯基]-乙基]-N-甲基-氨基]-丙基氨基}-3(2H)-哒嗪酮的方法。
英国专利说明书No.2 262 526提供了新的3(2H)-哒嗪酮-4-取代氨基-5-卤代-衍生物,其具有良好的抗心率失常性能和防止心室和心房纤维性颤动。式(I)5-氯-4-{3-[N-[2-(3,4-二甲氧基苯基)-乙基]-N-甲基-氨基]-丙基氨基}-3(2H)-哒嗪酮在上述专利说明书中予以了描述。
按照英国专利说明书 No.2 262 526,式(I)化合物的制备是通过式(XI)的4,5-二氯-3(2H)-哒嗪酮:
与式(X)的胺反应制备的:
该方法的缺点在于:所得到的是所需式(I)化合物和它的式(IA)区域异构体的混合物。
其主要成分是不需要的式(IA)异构体,而需要的式(I)化合物仅仅以百分之几的产率作为副产物存在。只有通过昂贵和烦琐的柱色谱才能将式(I)化合物从所得混合物中以纯净形式分离出来。该方法的另一个缺陷是:通过多步反应才得到昂贵的式(X)氨基组分要相当过量地(2.5-3倍摩尔)使用,使得该方法不够经济。
本发明的目的在于提供更具选择性的制备式(I)的5-氯-4-{3-[N-[2-(3,4-二甲氧基苯基)-乙基]-N-甲基-氨基]-丙基氨基}-3(2H)-哒嗪酮的方法,它没有迄今已知方法的缺点。
现已发现,按照本发明方法生产式(I)5-氯-4-{3-[N-[2-(3,4-二甲氧基苯基)-乙基]-N-甲基氨基]-丙基氨基}-3(2H)-哒嗪酮或其可药用的酸加成盐,可以实现上述目的,该方法包括:
a1)使通式(II)化合物:
其中X表示离去基团
与式(VI)的N-甲基-3,4-二甲氧基苯乙胺反应,或者
a2)使通式(III)化合物
其中R表示低级烷酰基、芳酰基或芳基-(低级烷酰基)
与含有离去基团X的试剂反应,然后将所获得的通式(II)化合物与式(VI)化合物反应;
或者
a3)使式(IV)的4-(3-羟基丙氨基)-3,5-二氯-哒嗪和适于引入R基团的试剂反应,
将所获得的通式(III)化合物与含有离去基团X的试剂反应,将所获得的通式(II)化合物与式(VI)化合物反应;或者
a4)使式(V)的3,4,5-三氯哒嗪
与3-氨基-1-丙醇反应,将所获得的式(IV)化合物和适于引入R基团的试剂反应,将所获得的通式(III)化合物与含有离去基团X的试剂反应,将所获得的通式(II)化合物与式(VI)化合物反应;或者
b1)从通式(IX)化合物中除去基团R(其中R如上所定义):
或者
b2)将式(VIII)化合物和适于引入R基团的试剂反应,
以及从所获得的通式(IX)化合物中除去基团R;或者
b3)使通式(VII)化合物
其中X如上所定义
与式(VI)化合物反应,
将所获得的式(VIII)化合物和适于引入R基团的试剂反应,以及从所获得的通式(IX)化合物中除去基团R;或者
b4)将式(IV)化合物与含有离去基团X的试剂反应,将所获得的通式(VII)化合物与式(VI)化合物反应,将所获得的通式(VIII)化合物和适于引入R基团的试剂反应,以及从所获得的通式(IX)化合物中除去基团R;以及
若需要的话,将所获得的式(I)化合物转化为其酸加成盐。
本发明基于以下发现:当使用式(V)3,4,5-三氯哒嗪作为起始物时,反应的区域选择性可得到显著提高。如果将式(V)化合物与3-氨基-1-丙醇反应,得到大约1∶1的所需式(IV)化合物和式(IVA)的其区域异构体的混合物:
使用式(V)化合物作为起始物的另一个优点在于式(IV)和(IVA)的异构体可以很容易地通过结晶进行分离,因而,对于工业规模的昂贵而烦琐的柱色谱就可以省去。本发明方法的另一个优点是:生成第一个中间体时,在合成的开始就将区域异构体分离开,因而,实施其它反应步骤和结束步骤,只使用一种区域异构体。所以,与迄今已知的方法相比较,可以减少损失并以较高的纯度从反应混合物中分离出所需产物。无法预见的是:式(IV)和(IVA)区域异构体能够如此简单地通过结晶进行分离,并且以如此高的产率转化为通式(II)和(III)化合物。
在本发明变体a)的第一步骤中,将式(V)3,4,5-三氯哒嗪和3-氨基-1-丙醇反应.该反应在有机溶剂中进行,作为反应介质,优选使用低级烷醇(如甲醇、乙醇或正丙醇,优选乙醇)或偶极非质子性溶剂(如乙腈或二甲基甲酰胺)。反应在酸结合剂存在下进行,为此目的,可以使用无机酸结合剂(例如:碱金属碳酸盐,如碳酸钠或碳酸钾;碱金属碳酸氢盐,如碳酸氢钠或碳酸氢钾),或有机酸结合剂(例如胺:如三乙胺或二乙基异丙基胺),根据本发明的优选实施方案,过量的反应物3-氨基-1-丙醇可以作为溶剂,反应可以在50℃-100℃温度下进行,优选在反应混合物的沸点下进行。
反应完成以后,将反应混合物进行后处理,优选除去溶剂,并用蒸馏水或5-15%的氯化钠溶液处理残留物。这样两种异构体可以容易地分离,沉淀物中富含不需要的式(IVA)异构体,可以通过简单的过滤从富含所需的式(IV)异构体的水溶液中分离出来。如果需要,两种异构体可以进行进一步纯化。式(IVA)异构体可以用醇重结晶进行提纯,而式(IV)化合物的纯化可以这样进行:用有机溶剂(如乙酸乙酯或卤代烃,如二氯乙烷或氯仿)萃取,然后干燥并蒸发萃取物,残留物用乙醚重结晶。
在本发明变体a)的第二反应步骤中,将所获得的式(IV)化合物与适于引入R基团的试剂反应,其中R为低级烷酰基(如:乙酰基、丙酰基或丁酰基)、芳酰基(如:苯甲酰基,任选带有选自卤素、烷氧基和三氟甲基的取代基)或芳基-(低级烷酰基)(如:苯乙酰基)。可以制备在R的位置含有乙酰基的通式(III)化合物并很好地用于合成。
用于所述合成第二步骤的式(IV)起始化合物可以进行纯化或不进行纯化。出人意料地发现,相比较于以经过纯化的式(IV)化合物为起始物,当式(IV)化合物未经纯化时,通式(III)化合物至少获得同样高的纯度和产率。如果制备在R的位置含有乙酰基的通式(III)化合物,可在过量的乙酸钠存在下,将式(IV)化合物与乙酸反应。优选冰乙酸作为反应介质并使用2.5-3倍摩尔过量的乙酸钠。反应可以在80℃-120℃,优选在大约100℃的温度下进行。反应混合物的后处理可以这样进行:用有机溶剂(优选二氯甲烷)萃取,然后干燥并蒸发有机相。用醇(优选甲醇)重结晶将产物纯化。
将变体a)的第三反应步骤所获得的式(III)化合物与含有离去基团X的试剂反应,其中X优选表示卤原子(如氯或溴)或烷基磺酰氧基(如苯磺酰氧基、对-甲苯磺酰氧基或对-溴苯磺酰氧基)。
优选经由通式(II)的中间体(其中X表示溴)进行所述反应。在此情况下,通式(III)化合物与氢溴酸水溶液反应。优选使用48%的氢溴酸水溶液.这样,可以在一个反应步骤中,以优异的产率将R基团从氨基上脱去和将羟基取代,得到式(II)4-(3-溴丙基氨基)-5-氯-3(2H)-哒嗪酮。反应在80℃-110℃,优选约98℃温度下进行。反应混合物很容易后处理,通过过滤或离心分离将产物分离出来并可任选用醇重结晶。在X位置含有溴的通式(II)化合物是特别优选的中间体,因为溴原子是易于裂解的离去基团。
在变体a)的下一个反应步骤中,将通式(II)化合物与N-甲基-N-[2-(3,4-二甲氧基苯基)-乙基]-胺(N-甲基-高藜芦胺)反应。反应在酸结合剂存在下于溶剂中进行,优选偶极非质子性溶剂(如丙酮、乙腈或二甲基甲酰胺)作为反应介质。可以使用无机化合物(例如:碱金属碳酸盐,如碳酸钠或碳酸钾;碱金属碳酸氢盐,如碳酸氢钠或碳酸氢钾),或有机化合物(例如胺,如三乙胺或二乙基异丙基胺)作为酸结合剂。反应在40℃-反应混合物沸点的温度下进行。也可以使用过量的式(VI)胺,它可以作为酸结合剂。
反应混合物可以通过已知方法进行后处理,例如将其蒸发,残留物倒入水中,用有机溶剂(如二氯甲烷或乙酸乙酯)萃取,将有机萃取物过滤、干燥以及通过结晶纯化。
本发明方法的变体b)的第一步骤中,将式(IV)化合物与含有离去基团X的试剂反应。当制备的通式(VII)化合物在X位置含有溴或氯时,将式(IV)化合物分别与亚硫酰溴或三溴氧磷,或者亚硫酰氯或三氯氧磷反应,反应于惰性有机溶剂中在-10℃-100℃温度下进行。作为溶剂,可以使用卤代烃(二氯甲烷、二氯乙烷、氯仿、三氯乙烯、氯苯或四氯化碳)、偶极非质子性溶剂(如乙腈)或芳族溶剂(如苯或甲苯)。制备X表示溴的通式(VII)化合物,也可以将式(IV)化合物在有机酸(例如乙酸或甲酸)中于20℃-150℃温度下和氢溴酸水溶液反应。
制备X表示烷基磺酰氧基或芳基磺酰氧基的通式(VII)化合物,可以在酸结合剂的存在下,在-20℃-60℃温度下于惰性溶剂中将式(IV)化合物与适当的磺酰氯反应。作为反应介质,可以使用卤代烃(如:三氯甲烷、二氯乙烷、氯仿、三氯乙烯、氯苯或四氯化碳)或芳族溶剂(如:苯或甲苯)。可以使用有机碱(如三乙胺或吡啶)作为酸结合剂。
在变体b)的下一个反应步骤中,将所获得的式(VII)化合物与式(VI)的胺反应。反应优选在酸结合剂的存在下于偶极非质子性溶剂(如:丙酮、乙腈、二甲基甲酰胺)中进行。可以使用无机化合物(如:碳酸钾或碳酸氢钾)或有机化合物(如:三乙胺)作为酸结合剂,过量的式(VI)胺也可以作为酸结合剂。反应在10℃-反应混合物沸点的温度下进行,反应混合物可以按照已知方法进行后处理,例如除去溶剂,残留物倒入水中,用有机溶剂(如二氯甲烷或乙酸乙酯)萃取,将有机萃取物过滤和干燥。
然后将获得的通式(VIII)化合物与适于引入基团R的试剂反应。在上述式(IV)化合物转化为式(III)化合物的相关条件下进行。优选制备在R位置上含有乙酰基的式(IX)化合物。为此目的,优选将式(VIII)化合物在冰乙酸中,在1-5倍摩尔过量的无水乙酸钠的存在下,于40℃-140℃,优选80℃-120℃温度下进行反应。
在变体b)的最后反应步骤中,除去通式(IX)化合物中的R基团。反应优选使用氢溴酸,尤其是48%的氢溴酸水溶液。
任选将所获得的通式(I)化合物转化为可药用的酸加成盐,盐的形成可以按照公知的方法,使用药业领域常用的酸来进行。可以使用无机酸(如盐酸、氢溴酸、磷酸、硫酸等)或有机酸(如马来酸、富马酸、柠檬酸、苹果酸、乳酸、琥珀酸等)。优选用盐酸或富马酸制备式(I)化合物的酸加成盐。
可以通过4,5-二氯-3(2H)-哒嗪酮与三氯氧磷反应制备式(V)化合物(T.Kuraishi:《药物通报》(pharm.Bull.)(Tokyo)4,497(1956)).
与迄今已知的方法相比较,本发明方法的优点如下:
-反应的区域选择性比已知方法要高很多;
-所需异构体可以简单地通过结晶从所得的区域异构体中分离,对于工业化规模,可以省去复杂而烦琐的柱色谱;
-区域异构体可以在合成的前阶段分离,然后在该方法的其余步骤只使用一种区域异构体;
-反应步骤可以以高产率实施(例如,式(II)和(III)的化合物的制备),以高产率和高纯度获得式(I)最终产物。
通过以下非限定性的实施例对本发明予以进一步阐明。
实施例1
4-(3-羟基丙基氨基)-3,5-二氯哒嗪(IV)和5-(3-羟基丙基氨基)- 3,4-二氯哒嗪(IVA)
将47.93g(0.261摩尔)3,4,5-三氯哒嗪溶于乙醇,并在搅拌下加入49.7m1(r=0.982g/cm3,0.65摩尔)3-氨基-1-丙醇。溶液加热至沸点,沸腾30分钟后,取样进行TCL分析(展开剂:10∶10∶0.5的乙酸乙酯∶丙酮∶三乙胺混合物,Rf值:(XI)=0.90,(IV)=0.48,(IVA)=0.32,未知结构的杂质=0.75)。反应一般进行30分钟至1小时,全部起始物被消耗完毕。然后将反应混合物蒸发,将13g氯化钠溶于蒸馏水中,搅拌下将所得溶液加入到蒸发过的混合物中,反应混合物在冰箱中于5℃放置过夜,将分离出来的晶体用10-12ml的冷蒸馏水洗涤,干燥沉淀物,得到27.7g(47.7%)粗产物(IVA)。M.P.:150-153℃。从甲醇中重结晶后,熔点升至157-158℃,其物理性质详见下文。
母液水溶液萃取5次,每次用乙酸乙酯200cm3,用硫酸镁干燥,滤过活性炭,蒸发至干,大部分残留粗产物为式(IV)化合物。
粗产物的产量:28.02g(48.32%),
根据HPLC分析,它含有7-8%的的(IVA)和1-2%未知结构的杂质,将粗产物按照以下方法从冷的乙醚中重结晶:
将300ml乙醚分5份加入其中并于室温下搅拌油性产物。每次将乙醚溶液倒出,并再使用新鲜的乙醚。将乙醚溶液合并,蒸发至100ml的体积,过滤析出的晶体,得到15.6g(26%)式(IV)化合物,M.p.65-66℃,提纯后,经HPLC分析,(IVA)<3%,而(IV)>97%。通过柱层析制备了少量标样用于精确HPLC方法。
HPLC方法:
柱:Ultrasphere SI 3mm.75cm×4.6mm.
洗脱剂:环己烷∶乙酸乙酯(1∶1)
流速:1.0ml/mm.
检测器:UV 254nm.
进样体积:20ml(0.8%稀释液)
保留时间:化合物(IV)5.13分钟,化合物(IVA)13.46分钟
4-(3-羟基丙基氨基)-3,5-二氯哒嗪(IV)的物理-化学性质
M.p.:65-66℃
TLC:乙酸乙酯∶三乙胺=20∶0.5
Rf=0.36
C7H9Cl2NO3(222.08)的元素分析:
C H Cl N
计算值: 37.86% 4.09% 31.93% 18.92%
实测值: 37.62% 4.12% 31.71% 18.67%
IR(KBr)νcm-1:3249,2947,1591,1454,1390,1353,1212,1177,1124,1075,1037,908,683,522,460
1H-NMR(DMSO):δ8.70[s,(1H)哒嗪C-6]
6.8[t,(1H)4-NH],4.7[t,(1H)OH],
3.74[qa,(2H)N-CH2],3.5[qa,(2H)CH2-O-],1.73[m,(2H)C-CH2-C].
13CNMR(DMSO):δppm:150.8,116.0,140.1,114.7(哒嗪碳原子),(60 C-OH),(43.0 NH-C),(31.9 C-CH2-C).
5-(3-羟基丙基氨基)-3,5-二氯哒嗪(IVA)的物理-化学性质
M.p.157-158℃
TLC:乙酸乙酯∶三乙胺=20∶0.5
Rf=0.16
式C7H9Cl2N3O(222.08)的元素分析
C H Cl N
计算值: 37.86% 4.09% 31.93% 18.92%
实测值: 37.68% 4.11% 31.77% 18.73%
IR(KBr)νcm-1:3269,2935,1568,1334,1283,1224,1139,1070,1043,861,830,795,661,540,514.
1H-NMR(DMSO)δppm:8.73[s,(1H)哒嗪C-6]
7.59[t,(1H)5-NH],4.66[t,(1H)OH],
3.4-3.6[m,(4H)CH2-X,X=杂原子],1.73
[m,(2H)C-CH2-C].
5位上的NH质子和6位上的哒嗪质子的空间邻近(stereoscopicvicinity)已经通过DNOE实验得到证实
13CNMR(DMSO):δppm:152.1,143.7,137.2,114.4(哒嗪碳原子),(58.4 C-OH),(39.9 C-NH),(31.4 C-CH2-C).
实施例2
制备4-N-乙酰基-4-N-(3-乙酰氧基丙基)-5-氯-3(2H)哒嗪酮(III)
方法A
将3g(13.5毫摩尔)4-(3-羟基丙基氨基)-3,5-二氯哒嗪(IV)和3g(36.5毫摩尔)无水乙酸钠的混合物悬浮于30cm3冰乙酸中,将混合物沸腾3小时,(TLC:乙酸乙酯∶丙酮∶三乙胺=10∶10∶0.5)。起始物(Rf=0.48)消耗完毕,然后将反应混合物冷却,向其中加入10.0cm3蒸馏水,,将混合物萃取三次,每次用二氯乙烷50cm3,合并有机相,硫酸镁干燥,滤过活性炭并蒸发,将粗的油状残留物溶于5cm3热的甲醇.冷却,开始析出4-N-乙酰基-4-N-(3-乙酰氧基丙基)-5-氯-3(2H)-哒嗪酮(III),将析出的晶体过滤,依次用冷的甲醇和乙醚洗涤,产量:2.0g(51.6%)
方法B
将28g(0.12摩尔)粗品式(IV)化合物和28g(0.34摩尔)无水乙酸钠的混合物悬浮于280cm3冰乙酸中,将混合物加热至沸腾,反应如上所述进行。然后将反应混合物冷却,滤去乙酸钠并用冰乙酸洗涤.将母液在真空条件下蒸发。为了完全除去乙酸,加入2×50cm3的甲苯并再次蒸发。然后将残留物溶于100cm3蒸馏水,将含水母液萃取三次,每次用二氯乙烷100cm3,合并有机相,硫酸镁干燥,滤过活性炭并蒸发。将残留的粗产物(29-30g)溶于15-20cm3热的甲醇,活性炭脱色并趁热过滤,冷却析出产物。过滤,并依次用冷的甲醇和冷的乙醚洗涤。产量:16-20g(45-50%)
按照方法A和B任一种制备的式(III)化合物,其物理-化学性质是相同的。
4-N-乙酰基-4-N-(3-乙酰氧基丙基)-5-氯-3(2H)-哒嗪酮(III)的物
理-化学性质
M.p.:108-110℃.
TLC:乙腈∶甲醇9∶1,Rf=0.75
式C11H14ClN3O4的元素分析:
C H Cl N
计算值: 45.92% 4.91% 12.32% 14.61%
实验值: 45.63% 5.01% 12.36% 14.40%
IR(KBr)νcm-1:3400-2800[哒嗪环(NH-CO)],1729,1676(酰胺)1593,1445,1406,1362,1321,1256,1205,1172,1128,1099,1083,1032,971,945,888,845,831.777,741,637,610,569,448,427.
1H-NMR(400MHz,CDCl3)δppm:12.8[s,(1H)哒嗪酮-NH],7.97[s,(1H)哒嗪酮C-6H],4.12[t,(2H)J=6.5Hz,-CH2O],{3.8[m,(1H)和3.7[m,(1H),-N-CH2],2.03[s,(3H),CH3],1.97[s,(3H)CH3],1.89[m,(2H),C-CH2-C]。
13CNMR(400MHz CDCl3)δppm:171.07,169.68,(乙酰基-羰基碳原子),159.87(CO-哒嗪酮),138.2,138.4,139.9(哒嗪酮环的碳原子),62.0 CH2-O),44.2(CH2-N),27.4(CH2),21.7和20.9(CH3碳原子)
方法B的优点在于避免了从乙醚中重结晶的物质损失。
实施例3
4-(3-溴丙基氨基)-5-氯-3(2H)-哒嗪酮(II)
在一个可以通过Du Pont螺帽密闭的烧瓶中,将30.5g(0.106摩尔)4-N-乙酰基-4-N-(3-乙酰氧基丙基)-5-氯-3(2H)-哒嗪酮(III)悬浮于136cm3的48%氢溴酸水溶液中。搅拌下将反应混合物保持在96℃-98℃的温度下24小时(TLC:乙酸乙酯∶丙酮∶三乙胺=10∶10∶0.5,(III)Rf=0.73),在此期间后,起始物被消耗完毕,然后将反应混合物冷却,过滤析出的晶体并用冷的二氯甲烷洗涤,产量:27.3g(95%)。粗产物用100-110cm3异丙醇重结晶。产量:20.2g(73%)
4-(3-溴丙基氨基)-5-氯-3(2H)-哒嗪酮的物理-化学性质:
M.p.:116-118℃
TLC:乙酸乙酯∶丙酮∶三乙胺=10∶10∶0.5,Rf=0.73
式C7H9BrClN3O4(266.53)的元素分析:
C H Cl N
计算值: 31.55% 3.40% 13.30% 15.77%
实验值: 31.74% 3.45% 13.15% 15.70%
IR(KBr)νcm-1:3183,2800,2400,1545,1423,1374,1324.1269,1239,1214.1163,1107,1037,936,819,750,572.
1H-NMR(DMSO)δppm:12.45[s,(1H) NH-哒嗪],7.65[s,(1H)-哒嗪],6.4[s,(1H)4NH],3.78[t,(2H),N-CH2],3.58[t,(2H),Br-CH2],2.13[qa,(2H),CH2]
13CNMR(DMSO)δppm:156.93(CO-哒嗪酮),139.8,105.9(哒嗪酮环的碳原子),34.16(C-NH),41.88(C-Br),31.95(CH2)
实施例4
5-氯-4-{3-[N-[ 2-(3,4-二甲氧基苯基)-乙基]- N-甲基-氨基]-丙基氨基}-3(2H)-哒嗪酮(I)
将10.66g(0.04摩尔)4-(3-溴丙基氨基)-5-氯-3(2H)-哒嗪酮(II)、10.0g(0.05摩尔)N-甲基-(3,4-二甲氧基苯基)-乙胺(VI)和8g碳酸氢钾的混合物悬浮于80cm3丙酮中,反应混合物回流8-12小时,以TLC监示反应(展开剂:乙酸乙酯∶丙酮∶三乙胺=10∶10∶0.5(II Rf=0.76),(VI Rf=0.14)(I Rf=0.47))。趁热过滤混合物,用丙酮洗涤并将母液在真空条件下蒸发。向残留物中加入50cm3乙酸乙酯,滤去可能析出的无机物,再次蒸发滤液,所残留的粘稠的、油状产物(14-15g)用50cm3热水研磨两次,以除去未反应的式(VI)起始物。倾去温热的水溶液。将油状残留物溶于甲醇并用硫酸镁干燥,加入少量二异丙醚并冷却混合物,析出白色多孔状物,获得9g(59.0%)粗产物,M.p.89-90℃。用二异丙醚重结晶后,得到7.0g(46.0%)标题化合物。
5-氯-4-{3-[N-[2-(3,4-二甲氧基苯基)-乙基]-
N-甲基-氨基]
-丙基氨基}
-3
(2H)
-哒嗪酮
的物理-化学性质:
M.p.:90-92℃.
TLC:乙酸乙酯∶丙酮∶三乙胺=10∶10∶0.5
Rf=0.45
式C18H25ClN4O3(380.88)的元素分析:
C H Cl N
计算值: 56.76% 6.62% 9.31% 14.71%
实验值: 56.46% 6.68% 9.26% 14.85%
IR(KBr)νcm-1:3290,3111,2940,2860,2830,2780,2700,1640,1610,1570,1520,1445,1350,1260,1240,1140,1100,950,900,800,600.
1H-NMR(200MHz,CDCl3)δppm:1.7[s,(1H)哒嗪酮-NH],7.52[s,(1H)哒嗪酮-CH],6.75[m,(3H)Ar-H],6.62[t,(1H),NH],3.84和3.86[s,(6H),CH3O],3.85[m,(2H)丙基-CH2],2.72和2.65(m,(4H)乙基-CH2)2.56[m,(2H),丙基-CH2],2.33[s,(3H),N-CH3],1.80[m,(2H),丙基-CH2]。
13CNMR(200MHz CDCl3)δppm:157.69(哒嗪酮C3),148.46,146.94,132.64,120.20,111.73,110.93(CH3O-苯基-芳香碳原子),140.41(哒嗪酮C6),139.85(哒嗪酮C5),106.8(哒嗪酮C4),59.43(C1-丙基),55.54和55.49(O-CH3),54.83(C2-乙基),42.82(N-CH3),41.67(C3-丙基),32.87(CH2-Ar),27.66(C2-丙基).
实施例5
起始物的制备
将200g市购的4,5-二氯-3(2H)-哒嗪酮于1500cm3三氯氧磷中回流5小时。真空蒸馏掉过量的三氯氧磷。残留物倒入冰水中,过滤结晶并干燥。产量:200g(89%)3,4,5-三氯-哒嗪。M.p.58-60℃。
Claims (5)
2.根据权利要求1中所述的方法,其中的卤原子为氯或溴。
3.根据权利要求1的方法,所述溶剂为丙酮、乙腈或二甲基甲酰胺,所述的酸结合剂为碱金属碳酸盐、碱金属碳酸氢盐或胺。
4.根据权利要求3中所述的方法,其中的胺是三乙胺或过量的式(VI)反应试剂。
5.通式(II)化合物,
其中X表示溴。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/HU1998/000054 WO1999064402A1 (en) | 1998-06-05 | 1998-06-05 | Process for the preparation of a 3(2h)-pyridazinone- 4-substituted amino- 5-chloro- derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1347407A CN1347407A (zh) | 2002-05-01 |
CN1205190C true CN1205190C (zh) | 2005-06-08 |
Family
ID=10990122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988141701A Expired - Fee Related CN1205190C (zh) | 1998-06-05 | 1998-06-05 | 制备3(2h)-哒嗪酮-4-取代氨基-5-氯-衍生物的方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6800758B1 (zh) |
EP (1) | EP1082309B1 (zh) |
JP (1) | JP2004500314A (zh) |
KR (1) | KR20010052598A (zh) |
CN (1) | CN1205190C (zh) |
AT (1) | ATE304535T1 (zh) |
AU (1) | AU752967B2 (zh) |
BR (1) | BR9815967A (zh) |
CA (1) | CA2334220A1 (zh) |
DE (1) | DE69831612D1 (zh) |
HK (1) | HK1046529A1 (zh) |
MX (1) | MXPA00012044A (zh) |
NO (1) | NO318781B1 (zh) |
SK (1) | SK18492000A3 (zh) |
WO (1) | WO1999064402A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0103064A3 (en) * | 2001-07-26 | 2005-06-28 | Egis Gyogyszergyar Nyilvanosan | Polymorphic form of 5-chloro-4-(3-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino]-propylamino)-3-(2h)-piridazinone fumarate, its use, process for its preparation and pharmaceutical compositions containing it |
HU227237B1 (en) * | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
RU2712192C2 (ru) | 2014-07-31 | 2020-01-24 | Басф Се | Способ получения пиразолов |
PE20180327A1 (es) | 2015-05-11 | 2018-02-13 | Basf Se | Proceso para preparar 4-amino-piridazinas |
WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3048487A1 (de) | 1980-12-22 | 1982-07-29 | Cassella Ag, 6000 Frankfurt | Basisch substituierte pyridazine, ihre herstellung und ihre verwendung |
HU214320B (hu) | 1991-12-20 | 1998-03-02 | EGIS Gyógyszergyár Rt. | Eljárás új 3(2H)-piridazinon-származékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
-
1998
- 1998-06-05 CA CA002334220A patent/CA2334220A1/en not_active Abandoned
- 1998-06-05 MX MXPA00012044A patent/MXPA00012044A/es unknown
- 1998-06-05 CN CNB988141701A patent/CN1205190C/zh not_active Expired - Fee Related
- 1998-06-05 DE DE69831612T patent/DE69831612D1/de not_active Expired - Lifetime
- 1998-06-05 AU AU77834/98A patent/AU752967B2/en not_active Ceased
- 1998-06-05 EP EP98925869A patent/EP1082309B1/en not_active Expired - Lifetime
- 1998-06-05 US US09/701,732 patent/US6800758B1/en not_active Expired - Fee Related
- 1998-06-05 KR KR1020007013790A patent/KR20010052598A/ko active IP Right Grant
- 1998-06-05 AT AT98925869T patent/ATE304535T1/de not_active IP Right Cessation
- 1998-06-05 JP JP2000553411A patent/JP2004500314A/ja active Pending
- 1998-06-05 BR BR9815967-4A patent/BR9815967A/pt not_active IP Right Cessation
- 1998-06-05 WO PCT/HU1998/000054 patent/WO1999064402A1/en not_active Application Discontinuation
- 1998-06-05 SK SK1849-2000A patent/SK18492000A3/sk unknown
-
2000
- 2000-12-05 NO NO20006183A patent/NO318781B1/no unknown
-
2002
- 2002-10-31 HK HK02107909.3A patent/HK1046529A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20006183D0 (no) | 2000-12-05 |
EP1082309B1 (en) | 2005-09-14 |
JP2004500314A (ja) | 2004-01-08 |
US6800758B1 (en) | 2004-10-05 |
KR20010052598A (ko) | 2001-06-25 |
SK18492000A3 (sk) | 2001-06-11 |
EP1082309A1 (en) | 2001-03-14 |
CN1347407A (zh) | 2002-05-01 |
CA2334220A1 (en) | 1999-12-16 |
AU752967B2 (en) | 2002-10-03 |
NO318781B1 (no) | 2005-05-09 |
MXPA00012044A (es) | 2002-04-24 |
BR9815967A (pt) | 2004-06-22 |
HK1046529A1 (zh) | 2003-01-17 |
NO20006183L (no) | 2001-01-30 |
DE69831612D1 (de) | 2005-10-20 |
WO1999064402A1 (en) | 1999-12-16 |
AU7783498A (en) | 1999-12-30 |
ATE304535T1 (de) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108718527B (zh) | 用于制备化合物的方法 | |
CN1246295C (zh) | 用于制造抗叶酸剂的方法和中间体 | |
CN1070907A (zh) | 制备4-取代-1,4-二氢吡啶的新方法 | |
CN1942449A (zh) | 制备哒嗪酮化合物的方法 | |
CN1252072C (zh) | 4,6-二氨基嘧啶并[5,4-d]嘧啶的制备方法 | |
CN1178924C (zh) | 制备三唑啉硫酮衍生物的方法 | |
CN1578762A (zh) | 外消旋坦洛新游离碱和制备它的方法 | |
CN1922193A (zh) | 化学方法 | |
CN1205190C (zh) | 制备3(2h)-哒嗪酮-4-取代氨基-5-氯-衍生物的方法 | |
CN1083430C (zh) | 咔唑酮衍生物 | |
TWI291959B (en) | Process for preparing granisetron | |
EP2444393A1 (en) | Methods for producing cyclic benzamidine derivatives | |
CN1174961C (zh) | 制备三唑啉酮所用的中间体及其制备方法 | |
CN1232519C (zh) | 通过过渡金属催化的氨基化反应制备5-(1-哌嗪基)-苯并呋喃-2-甲酰胺的方法 | |
KR20110100628A (ko) | 아나그레리드 및 유사체의 제조 공정 | |
US10919855B2 (en) | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | |
CN1533378A (zh) | 制备喹唑啉的方法 | |
CN101052622A (zh) | 阿片中间体及其合成方法 | |
CN1127490C (zh) | 作为5-ht1a受体配体的1,4-双官能化环己烷衍生物 | |
US20030187274A1 (en) | Process for the preparation of 1,2,4- triazolin-5-one derivatives | |
CN1289495C (zh) | 新的哌啶基-烷基氨基-哒嗪酮衍生物、其制备方法以及包含所述化合物的药物组合物 | |
CN1284775C (zh) | 3-未取代-5-氨基-4-亚硝基吡唑化合物的制法以及2-肟基-3-氧代丙腈、3-亚肼基-2-肟基丙腈化合物和它们的制法 | |
CN1826329A (zh) | 烷氧基-(四唑-1-基)苯甲醛化合物及其生产方法 | |
CN1278805A (zh) | 新的杂环取代的α-羟基羧酸衍生物、其制备及其作为内皮素受体拮抗剂的用途 | |
TW202346260A (zh) | 用於製備5-氯-2-((乙氧基羰基)胺基)-3-甲基苯甲酸之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1046529 Country of ref document: HK |